Health score, price, valuation, risk signals, and key metrics at a glance.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Strongest: Cash & Earnings Quality (23/25); weakest: Profitability (5/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently above its 5-quarter median.
Currently below its 20-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
Operating margins dropped 147.1% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.
FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
Currently near its 15-quarter median.
FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.
Shares outstanding increased 24.9% — significant dilution, likely from stock compensation or capital raises.
